positions itself as a leading developer of neurodegenerative medicines.Dr Carol Worth will oversee the GMP manufacture of monepantel and the provision of clinical supplies
for our upcoming clinical studies. John Clark will lead global clinical operations as the Company
I wonder how this new Head of Manufacturing position differs to the appointment back in December 2023 of Dr Carol Worth as CMC Operations Manager?
“Dr Carol Worth will oversee the GMP manufacture of monepantel and the provision of clinical supplies for our upcoming clinical studies. John Clark will lead global clinical operations as the Company
positions itself as a leading developer of neurodegenerative medicines.”
positions itself as a leading developer of neurodegenerative...
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $85.08M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 18.5¢ | 17.5¢ | $30.65K | 170.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 387582 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 140877 | 3 |
View Market Depth
| Last trade - 10.53am 29/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |